HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- Innorna, a clinical-stage biotech company advancing RNA medicines, today announced that it has been nominated for the 2026 Prix Galien USA Best Startup Award.
Home
Immediapress
Pr Newswire
Comunicato stampa - contenuto promozionale
Responsabilità editoriale PrNewswire
BIOSAPIEN - THE REVOLUTIONARY CANCER PLATFORM DEVELOPER - NOMINATED AS "BEST STARTUP" IN THE 2026 PRIX GALIEN USA AWARDS
AIVITA Biomedical Nominated for 2026 Prix Galien USA Award
Innate Pharma Announces Conference Call and Webcast
innoscripta SE: Successful US Market Entry - Clusterix Addresses New IRS Documentation Requirements under Form 6765
BIOSAPIEN - THE REVOLUTIONARY CANCER PLATFORM DEVELOPER - NOMINATED AS "BEST STARTUP" IN THE 2026 PRIX GALIEN USA AWARDS
2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
/C O R R E C T I O N -- Innovent Biologics/
AIVITA Biomedical Nominated for 2026 Prix Galien USA Award
Outcome of Innate Pharma’s 2026 Annual General Meeting
